# Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

> **NCT00275054** · PHASE3 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 825 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT00275054
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-07
- **Final completion:** 2015-06
- **Target enrollment:** 825 (ACTUAL)
- **Last updated:** 2019-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275054, "Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00275054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*